Abstract
Galectin-3 is a beta-galactoside-binding lectin with an established association to inflammatory and fibrotic conditions. We investigated galectin-3 levels in 68 recipients of allogeneic hematopoietic cell transplantation (HCT) to look for associations with chronic graft-versus-host disease (cGVHD). Plasma galectin-3 concentrations were measured at 1 year post-HCT and correlated with clinical data collected from individual medical records. The median serum galectin-3 level at that time point was 14.9 ng/mL (range, 5.5–61.6), which was significantly higher than that among healthy controls (14.9 versus 6.2, p < 0.001). Furthermore, patients with active cGVHD at the time of sample collection had higher median levels as compared to those without cGVHD (16.9 versus 13, p = 0.03). In a multivariable logistic model, there was no significant association between the presence of cGVHD at the date of sample collection and elevated galectin-3 levels (>14.9 ng/mL) (odds ratio [OR]: 2.03 (0.60, 6.88), p = 0.26). However, among patients with cGVHD at the date of sample collection, active systemic corticosteroid therapy was associated with elevated galectin-3 levels (OR: 20.32 (1.66, 249.39), p = 0.02). Furthermore, in a competing risk regression model, elevated galectin-3 levels at 1 year post-HCT were not associated with future development of moderate or severe cGVHD (OR: 1.24 (0.21, 7.45), p = 0.81). In conclusion, plasma galectin-3 concentrations are elevated in recipients of allo-HCT, especially among patients with cGVHD. Further investigation will be required to determine whether galectin-3 has a pathophysiologic role in cGVHD or serves as a marker of ongoing inflammation following allogeneic HCT.
Article PDF
Avoid common mistakes on your manuscript.
References
Socie, G, Ritz, J. Current issues in chronic graft-versus-host disease. Blood 2014;124;374–84.
Pidala, J, Kurland, B, Chai, X, Majhail, N, Weisdorf, DJ, Pavletic, S, et al. Patient-reported quality of life is associated with severity of chronic graft-versus-host disease as measured by NIH criteria: report on baseline data from the Chronic GVHD Consortium. Blood 2011;117;4651–57.
Wolff, D, Greinix, H, Lee, SJ, Gooley, T, Paczesny, S, Pavletic, S, et al. Biomarkers in chronic graft-versus-host disease: quo vadis? Bone Marrow Transplant 2018;53;832–37.
Li, LC, Li, J, Gao, J. Functions of galectin-3 and its role in fibrotic diseases. J Pharmacol Exp Ther 2014;351;336–43.
de Boer, RA, van Veldhuisen, DJ, Gansevoort, RT, Muller Kobold, AC, vanGilst, WH, Hillege, HL, et al. The fibrosis marker galectin-3 and outcome in the general population. J Intern Med 2012;272;55–64.
Ohshima, S, Kuchen, S, Seemayer, CA, Kyburz, D, Hirt, A, Klinzing, S, et al. Galectin 3 and its binding protein in rheumatoid arthritis. Arthritis Rheum 2003;48;2788–95.
Lok, DJ, Van Der Meer, P, de la Porte, PW, Lipsic, E, Van Wijngaarden, J, Hillege, HL, et al. Prognostic value of galectin-3, a novel marker of fibrosis, in patients with chronic heart failure: data from the DEAL-HF study. Clin Res Cardiol 2010;99;323–28.
Ho, JE, Liu, C, Lyass, A, Courchesne, P, Pencina, MJ, Vasan, RS, et al. Galectin-3, a marker of cardiac fibrosis, predicts incident heart failure in the community. J Am Coll Cardiol 2012;60; 1249–56.
Faludi, R, Nagy, G, Tokes-Fuzesi, M, Kovacs, K, Czirjak, L, Komocsi, A. Galectin-3 is an independent predictor of survival in systemic sclerosis. Int J Cardiol 2017;233;118–24.
Zeiser, R, Blazar, BR. Pathophysiology of chronic graft-versus-host disease and therapeutic targets. N Engl J Med 2017;377; 2565–79.
Cutler, CS, Koreth, J, Ritz, J. Mechanistic approaches for the prevention and treatment of chronic GVHD. Blood 2017;129;22–29.
Jagasia, MH, Greinix, HT, Arora, M, Williams, KM, Wolff, D, Cowen, EW, et al. National institutes of health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. The 2014 diagnosis and staging working group report. Biol Blood Marrow Transplant 2015;21; 389–401.e381.
MacDonald, KP, Hill, GR, Blazar, BR. Chronic graft-versus-host disease: biological insights from preclinical and clinical studies. Blood 2017; 129;13–21.
Alexander, KA, Flynn, R, Lineburg, KE, Kuns, RD, Teal, BE, Olver, SD, et al. CSF-1-dependant donor-derived macrophages mediate chronic graft-versus-host disease. J Clin Invest 2014;124;4266–80.
Kolatsi-Joannou, M, Price, KL, Winyard, PJ, Long, DA. Modified citrus pectin reduces galectin-3 expression and disease severity in experimental acute kidney injury. PLOS ONE 2011;6;e18683.
Lu,Y, Zhang,M, Zhao, P, Jia, M, Liu, B, Jia, Q , et al. Modified citrus pectin inhibits galectin-3 function to reduce atherosclerotic lesions in apoE-deficient mice. Mol Med Rep 2017;16;647–53.
Navarro-Alvarez, N, Goncalves, B, Andrews, AR, Wang, Z, Wang, Z, Harrington, E, et al. The effects of galectin-3 depletion apheresis on induced skin inflammation in a porcine model. J Clin Apher 2018;33;486–93.
Author information
Authors and Affiliations
Corresponding author
Additional information
Peer review under responsibility of the International Academy for Clinical Hematology
Data availability statement: The data that support the findings of this study are available from the corresponding author, upon reasonable request.
Rights and permissions
This is an open access article distributed under the CC BY-NC 4.0 license (http://creativecommons.org/licenses/by-nc/4.0/).
About this article
Cite this article
DeFilipp, Z., Navarro-Alvarez, N., Li, S. et al. Elevated Galectin-3 Plasma Concentrations in Recipients of Allogeneic Hematopoietic Cell Transplantation. Clin Hematol Int 1, 201–204 (2019). https://doi.org/10.2991/chi.d.190823.001
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.2991/chi.d.190823.001